Welcome to our dedicated page for Genenta Science S.p.A. American Depositary Shares news (Ticker: GNTA), a resource for investors and traders seeking the latest updates and insights on Genenta Science S.p.A. American Depositary Shares stock.
Genenta Science S.p.A. (symbol: GNTA) is a cutting-edge biotechnology company specializing in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and various types of cancer. The company leverages an innovative gene transfer strategy into autologous hematopoietic stem/progenitor cells (HSPCs) to target interferon-α expression specifically to tumor-infiltrating monocytes/macrophages. Utilizing a genetically modified, HIV-derived lentiviral vector, Genenta delivers the therapeutic gene into HSPCs, enabling these cells to selectively express interferon within the tumor microenvironment, thereby minimizing systemic toxicity.
One of Genenta's flagship products, Temferon, is designed to treat glioblastoma multiforme, a highly aggressive brain tumor. Another key product focuses on TIE2-expressing monocytes (TEMs), which are engineered to attack solid tumors using an innovative combination of transcriptional and microRNA-mediated control mechanisms.
In recent developments, Genenta Science has expanded its research to include refractory advanced genitourinary malignancies, such as renal cell cancer, as a second indication. The company's latest news highlights preliminary data from its ongoing Phase 1/2 clinical trials, demonstrating promising results in the dose-ranging stage.
With its headquarters in Milan, Italy, and extensive clinical operations in New York, Genenta Science is at the forefront of immuno-oncology, aiming to harness the body's own immune system to combat cancer effectively and safely. The company remains committed to advancing its pipeline and achieving breakthroughs in cancer treatment.
- Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication.
- Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial.
Italy on the Move, a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025, will showcase Italy as a leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals. The event, hosted by The Italian Trade Agency and the Ministry of Foreign Affairs, will take place on January 15th, 2025, at INNOVIT in San Francisco.
The event will feature notable speakers including Italian Ambassador H.E. Mariangela Zappia and include a panel discussion on Transatlantic Partnerships in Life Sciences. Five Italian startups - Aavantgarde, Butterfly Decisions, Cellply, Medlea, and Sibylla Biotech - will present pitch presentations. The event highlights Italy's €270 Billion life sciences sector and aims to foster innovation and collaboration between Italian and American stakeholders.
Genenta Science (NASDAQ: GNTA) has enhanced its partnership with AGC Biologics by securing an exclusive GMP manufacturing suite at AGC's Cell and Gene Center of Excellence in Milan. This strategic amendment aims to strengthen the production of Genenta's cell therapy products, ensuring cGMP compliance.
The company's metastatic Renal Cell Cancer (mRCC) Phase 1/2a trial, initiated in Q4 2024, aims to treat six patients by H1 2025, while the Glioblastoma Multiforme (GBM) study continues. Genenta plans to manufacture 27 autologous drug products in 2025.
Recent preclinical and clinical studies highlight Temferon's capability to reprogram the tumor microenvironment, inhibit myeloid cell-induced immune suppression, and enhance T-cell responses. The company suggests potential synergies with immunotherapeutic strategies, including immune checkpoint inhibitors and CAR-T cell therapies.
The Italian Trade Agency (ITA) and the Ministry of Foreign Affairs will host the eighth 'Italy on the Move' event alongside the 43rd J.P. Morgan Healthcare Conference 2025 in San Francisco. The event, scheduled for January 15, 2025, at INNOVIT, aims to showcase Italy's €270 billion life sciences sector and investment opportunities.
The Italian life sciences ecosystem, contributing 11% to the country's GDP, has attracted nearly 50 multinational companies. Italy ranks first among EU economies in pharma CDMO manufacturing value and fourth worldwide in Life Sciences patents productivity.
The event will feature keynote speakers including Ambassador Mariangela Zappia and Director General Mauro Battocchi, followed by a panel discussion on 'Navigating Transatlantic Partnerships in Life Sciences' moderated by Audrey Greenberg. Notable panelists include executives from Rubedo Life Sciences, Bracco Imaging, Menarini Group, TPG Capital, and Genenta Science (NASDAQ: GNTA). Five Italian startups - Aavantgarde, Butterfly Decisions, Cellply, Medlea, and Sibylla Biotech - will present pitch presentations.
Genenta Science (NASDAQ: GNTA) announces CEO Pierluigi Paracchi's participation as a speaker at the Italy-U.S. meeting on 'Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective' at the U.S. Senate on October 25th, 2024. The event, organized by the U.S. National Security Commission on Emerging Biotechnology and Italian Embassy, features distinguished speakers including Michelle Rozo, Mariangela Zappia, and Patrick Soon-Shiong.
As moderator of the Italian Working Group on Internationalization of Biotech Sector (NWTIB), Paracchi will present the Interim Report, emphasizing the strategic importance of biotechnologies post-pandemic and Italy's role in preserving and advancing these innovations while attracting international investments.
Genenta Science (NASDAQ: GNTA) has received approval from AIFA for a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), expanding potential applications for its flagship product, Temferon™. This approval aligns with EMA standards. The company's ongoing TEM-GBM development program has completed a Phase 1 dose-ranging trial, confirming no dose-limiting toxicities across 24 patients. Temferon-derived cells remained detectable for over two years post-infusion, with treatment associated with a median survival of 16.8 months and a 25% increase in 2-year overall survival.
The new mRCC trial, targeting high-risk patients with a median overall survival of less than 2 years after multiple therapies, is expected to start in Q4 2024. Recent preclinical studies show synergy between Temferon and other immunotherapies in solid tumors. Genenta will present these developments at upcoming events, including Maxim Group's 2024 Healthcare Virtual Summit and the Society for Neuro-Oncology Annual Meeting.
Genenta Science (NASDAQ: GNTA) recently appointed five new directors to its Board of Directors, including John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider. The company aims to leverage the expertise of these new members to further develop its cell-based platform for treating solid tumors. The shareholders' meeting held on May 2, 2024, marked a significant step towards strengthening the company's leadership and strategic direction.
FAQ
What is the current stock price of Genenta Science S.p.A. American Depositary Shares (GNTA)?
What is the market cap of Genenta Science S.p.A. American Depositary Shares (GNTA)?
What is Genenta Science's main area of research?
What are some of the key products developed by Genenta Science?
How does Genenta's gene therapy work?
What recent advancements has Genenta Science made?
Where is Genenta Science headquartered?
What is Temferon?
What are TIE2-expressing monocytes (TEMs)?
How does Genenta ensure the safety of their gene therapies?
What is the significance of the Phase 1/2 clinical trials?
Who can I contact for more information about Genenta Science?
